Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice

NCT Number	NCT07557498
Lead Sponsor	Bristol-Myers Squibb
Conditions	Obstructive Hypertrophic Cardiomyopathy (oHCM)
Enrollment	362 participants
Start Date	2026-01-15
Primary Completion	2026-12-14 (estimated)
Study Completion	2027-06-17 (estimated)
Updated on ClinicalTrials.gov	2026-04-29